Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates
Open Access
- 8 March 2019
- journal article
- research article
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 9 (3) , 123-127
Abstract
Despite rapid advances in diagnostic and treatment approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading cause of neoplasm-related deaths worldwide, in large part due to its considerable metastasis and drug resistance. For developing new anticancer strategies, rapid progression of multimodal nanomedicines and nanoconjugates has provided promising treatment modalities for effective therapy of cancer. The limitations of cancer chemotherapy might be overcome through the use of such nanosized therapeutics, including nanoconjugates of monoclonal antibodies (mAbs) along with drugs and organic/inorganic nanoparticles. CRC cells express various molecular markers against which mAbs can be designed and used as targeting/therapeutic agents. This editorial highlights the importance of such targeted nanosystems against CRC.Keywords
This publication has 60 references indexed in Scilit:
- Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibodyBiomaterials, 2013
- Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosisCritical Reviews in Oncology/Hematology, 2013
- Targeting HER Receptors in CancerCurrent Pharmaceutical Design, 2013
- Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-AnalysisPLOS ONE, 2012
- Receptor-targeted nanocarriers for therapeutic delivery to cancerMolecular Membrane Biology, 2010
- Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterationsMolecular Cancer, 2010
- Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal CancerClinical Cancer Research, 2010
- Induction of Human Alveolar Epithelial Cell Growth Factor Receptors by Dendrimeric NanostructuresInternational Journal of Toxicology, 2009
- The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR AgentsMolecular Cancer Research, 2007
- Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectivesAnnals of Oncology, 2005